Operator's Information

Alan C. Yeung, MD

Country USA
Specialty Interventional Cardiologist
  1. The UPSTREAM Management of Aortic Stenosis
  2. New Device Platform to Prevent Structural Heart Intervention Complications
  3. Hostile Anatomy - LVOT Calcification
  4. How Recent Guidelines will Change the Practical Indication of TAVR in the Coming Years?
  5. [Featured Lecture 1] The UPSTREAM Management of Aortic Stenosis
  6. Balloon Expandable Valves. New Understandings about Sizing, Positioning, and Repeating
  7. Overview of Cardiac Arrest During Structural Heart Intervention
  8. Optimal Valve Choice in Various TAVR: A Complex Equation to Select One
  9. Antithrombotic Strategy in PCI and AF Patients: Updated Strategy
  10. Many Many Stents: What Should I Select?
  11. Cerebral Protection During TAVR: Why and How?
  12. Expanding Indication of TAVR: Ongoing Trials and Expectations
  13. Sapien 3 THV with Future Coronary Access
  14. Case 1: Complex LM/Multivessel Disease - Hybrid Revascularization
  15. PCI, CABG, or Both: Current Status of Hybrid Coronary Revascularization
  16. Expert Case Review: PCI for Severely Calcified In-Stent Restenosis
  17. TAVR in Low Risk Patients
  18. Sapien 3 or Evolut R: Different Indications?
  19. MV and TV Intervention: Preparing for the Next Revolution
  20. TAVR: Advancing Your Skills: Beyond the Basics
  21. How to Manage Complication TAVR Case
  22. Updates on Antiplatelet Therapy in Cardiovascular Disease
  23. Contemporary DES Thrombosis and Restenosis: Incidence, Mechanisms, and Treatment
  24. Evolving TAVR Indications (Heart Failure, Asymptomatic AS, and AR)
  25. Contemporary and Future Metallic DES: What Do We Expect More from Ongoing PCI Trials?
  26. MV and TV Repair - Current Status and Innovative Future
  27. TVT Registry
  28. TAVR Clinical Trials
  29. PVL: How to Prevent and How to Treat?
  30. Sizing Strategy and PVL Management: Most Experienced Strategy
  31. TAVR for Low Risk Patients: Interventionist\'s Viewpoint
  32. The Evolution of Mitral and Tricuspid Valve Interventions: What It Is? and Where It Needs to Go?
  33. Experience, Current Status and Future of BRS in U.S. Real-World
  34. Technical Lessons for TAVR; Expert Experience
  35. Award Tribute
  36. Comparative Outcomes of Contemporary DES; Are There Major Difference?
  37. Low Coronary Ostium with Narrow or Wide Sinus
  38. Early Discharge Check List to Be Minimalist
  39. Frailty Assessment and How to Define Futile TAVR
  40. Next Issue: How to Manage Failed Transcatheter Heart Valve
  41. Complete Revascularization- The Future Mode of Revascularization in STEMI?
  42. Balloon Expandable System
  43. New Transcatheter Heart Valves
  44. Edward Sapien: Transfemoral
  45. TAVI: Future Perspectives
  46. Edward Sapien
  47. Coronary Obstruction: Treatment and Prevention
  48. Myocardial Bridge: Incidental Finding or Clinical Pathology?
  49. Invited Case Presentation & Focus Review: Multi-vessel Intervention
  50. Mediate a Dispute: Summary
  51. Promus-Element Stent
  52. In-Stent Restenosis - Stop ISR: How to Treat DES-ISR?: Summary
  53. The Updated Evidence-based Guidelines for the Use of Antiplatelet Therapies in ACS
  54. Clinical Decision Making in Patients with Left Main Disease
  55. Use of OCT in Treating a LAD/Diagonal Bifurcation Lesion
  56. Is It Real? Cytochrome P450 Genetic Polymorphisms, Varying Response to Clopidogrel, and Link to Clinical Outcomes : Global Perspective
  57. How to Teach and Train Innovation: US Approach
  58. Experiences of 2nd Generation OCT in Assessment of Complex Coronary Lesions; Can It Give Us Additive Useful Information?
  59. Association between CYP2C19 Genotype and Adverse Clinical Outcomes among PCI Patients: A Meta-analysis
  60. Optimizing the Role of New Anti-thrombotic Regimens in ACS - When, What and Why?
  61. Endothelial Dysfunction Associated with DES: How Important?
  62. New Technologies for Bifurcation: Main Vessel Centric vs Side-Branch Centric
  63. New Devices in Bifurcation Lesions: Do We Really Need One?
  64. Bifurcation Stenting: Implications of the Norfic Study
  65. What Makes Endeavor Different
  66. D2B: An Alliance for Quality
  67. TAXUS Real-World Experience from ARRIVE Registry
  68. Is There a Safety Advantage in the PC Based DES Systems? Possible Mechanisms
  69. Systemic Therapy: Pharmacologic Approach or Cell/Gene Therapy
  70. Technical Aspects and an Update on the EU and US ZOMAXX Clinical Trials
  71. What Are the Proper End Points for DES Trials?
  72. IVUS in Complex PCI
  73. Regional Photodynamic Therapy for Vulnerable Plaque Stabilization I: Antrin
  74. ABT 578 Drug-Eluting Stents II: Preclinical Observations and the Clinical Trial Strategy for the Abbott ZoMax Stent
  75. What Are The Proper End Points for DES Trial
  76. Adjunctive Platelet Glycoprotein IIb/IIIa Receptor Inhibition with Tirofiban before Primary Angioplasty Improves Angiographic Outcomes: Results of the TIrofiban Given in the Emergency Room before Primary Angioplasty(TIGER-PA) Pilot Trial
  77. Percutaneous Bypass: Rebirth as Treatment for CTO
  78. Bifurcation Stenoses: Is There a Solution in Sight ?
  79. Brachytherapy vs DES: Is the Answer in yet ?
Conference Slides
Category